search

All clinical trials

Results 460351-460360 of 470744

Post Marketing Surveillance Study of Cuprimine

Scleroderma

Cuprimine (penicillamine) was made available in the Philippines by the Sponsor under a Compassionate Special Permit issued by the Bureau of Food and Drugs. Physicians were able to request the drug for their patients from the Sponsor. A Clinical Study Report form was completed for each purchase of Cuprimine.

No longer available2 enrollment criteria

Aprotinin US Special Access Protocol

Postoperative Hemorrhage

This is a special access protocol that will allow physicians access to aprotinin during the temporary marketing suspension. The program will provide aprotinin for treatment of surgical patients undergoing coronary artery bypass graft (CABG) surgery requiring cardiopulmonary bypass (CPB) who are at increased risk of bleeding and transfusion when, in the opinion of the treating physician, the patients require it, there is no acceptable alternative therapy, and when there is a clearly favorable benefit-risk for the drug in that individual patient.

No longer available11 enrollment criteria

An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer...

Non Small Cell Lung CancerCancer of the Head and Neck

The purpose of this study is to provide ZD1839 for those patients with locally advanced and/or metastatic non-operable non-small cell lung cancer (stage III or IV) or recurrent and/or metastatic squamous cell head and neck cancer who receive the therapy on an expanded access basis due to their inability to meet eligibility criteria for on-going recruiting trials, inability to participate in other clinical trials (e.g., poor performance status, lack of geographic proximity), or because other medical interventions are not considered appropriate or acceptable.

Approved for marketing8 enrollment criteria

Prochymal Expanded Access Treatment for Pediatric Patients Who Have Failed Steroids for Acute GVHD...

Graft vs Host DiseaseGraft-Versus-Host Disease

This protocol allows for the treatment of pediatric patients, male and female, between the ages of 2 months and 17 years. Patients must have failed steroid treatment for Grade B-D acute GVHD.

No longer available7 enrollment criteria

The Change of Pulmonary Blood Flow During One Lung Ventilation

One Lung Ventilation

To investigate the changes of regional pulmonary blood flow in nondependent lung by transesophageal echocardiography during one lung ventilation

Temporarily not available5 enrollment criteria

Compassionate Use Trial for Unresectable Melanoma With Ipilimumab

Melanoma

The primary objective of the study is to provide treatment with Ipilimumab to subjects who have serious or immediately life-threatening unresectable Stage III or Stage IV melanoma, who have no alternative treatment options, and whose physicians believe, based upon available data on benefit and risk, that it is appropriate to administer Ipilimumab at a dose of 3 mg/kg induction (with re-induction, if eligible), or for eligible subjects previously enrolled in Ipilimumab studies CA184-042, CA184-078, CA184-087, MDX010-16, or MDX010-20.

No longer available37 enrollment criteria

Dose-Dense Therapy in Aggressive Lymphoma

Lymphoma

To investigate if a dose-dense chemotherapy with weekly chemotherapy compared to standard treatment every 3 weeks results in better survival in aggressive non-Hodgkin's lymphoma.

No longer available11 enrollment criteria

A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome...

Irritable Bowel Syndrome With ConstipationChronic Idiopathic Constipation

To provide tegaserod to eligible women adult patients who did not have satisfactory improvement of their irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) symptoms with other available treatment(s) and / or patients who had satisfactory improvement of their symptoms with prior tegaserod treatment for IBS-C or CIC.

No longer available16 enrollment criteria

Emergency/Compassionate Use - Membranous VSD Occluder

MembranousVentricular3 more

Emergency/Compassionate use of the AMPLATZER Membranous VSD Occluder

No longer available1 enrollment criteria

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

Neoplasms

This protocol is for the treatment of toxic plasma methotrexate concentrations (>1 micromole per liter) in patients with delayed methotrexate clearance due to impaired renal function

Approved for marketing4 enrollment criteria
1...460354603646037...47075

Need Help? Contact our team!


We'll reach out to this number within 24 hrs